Compare AL & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AL | KRYS |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | 165 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.3B |
| IPO Year | 2011 | 2017 |
| Metric | AL | KRYS |
|---|---|---|
| Price | $64.07 | $244.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $60.50 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 2.2M | 286.6K |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | 96.53 | ★ 275.72 |
| EPS | ★ 8.62 | 6.66 |
| Revenue | ★ $2,908,265,000.00 | $373,164,000.00 |
| Revenue This Year | $10.26 | $36.14 |
| Revenue Next Year | $6.10 | $41.80 |
| P/E Ratio | ★ $7.43 | $36.72 |
| Revenue Growth | 6.25 | ★ 54.51 |
| 52 Week Low | $38.25 | $122.80 |
| 52 Week High | $64.30 | $248.60 |
| Indicator | AL | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 61.81 | 81.72 |
| Support Level | $63.93 | $213.83 |
| Resistance Level | $64.16 | $241.65 |
| Average True Range (ATR) | 0.15 | 7.53 |
| MACD | -0.00 | 2.17 |
| Stochastic Oscillator | 70.45 | 89.34 |
Air Lease Corp is an aircraft leasing company based in the United States. It is engaged in purchasing commercial jet aircrafts directly from aircraft manufacturers and leasing those aircraft to airlines throughout the world to generate attractive returns on equity. The company also sells aircraft from its fleet to third parties, including other leasing companies, financial services companies, airlines, and other investors, and offers fleet management services to investors and owners of aircraft portfolios for a management fee. Geographically, it derives a majority of its revenue from the Asia-Pacific region and the rest from Europe, Middle East and Africa, Central America, South America, Mexico, the United States, and Canada.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.